Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data Veradermics, Inc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Research and development
23.3
62.1
General and administrative
3.5
10.3
Operating expenses
26.8
72.3
Operating income
-26.8
-72.3
Interest expense
0.59
0
Interest income
0.48
1.56
Other non-operating income
0.29
2.35
Pre-tax income
-26.5
-70
Income tax
0
0
Net income
-26.5
-70
EPS, basic
-37.05
-111.91
EPS, diluted
-37.05
-111.91
Shares, basic (weighted)
0.74
0.74
Shares, diluted (weighted)
0.74
0.74
Balance sheet
FY2025
FY2025
Cash and equivalents
53.1
21.8
Short-term investments
0
120
Other current assets
0.04
0.31
Total current assets
55.5
152
Property, plant and equipment
0
0.02
Lease right-of-use assets
0
0.1
Total assets
55.5
153
Accounts payable
2.25
2.13
Accrued liabilities
2.47
6.98
Total current liabilities
4.72
9.15
Lease liabilities
0
0
Total liabilities
4.72
9.16
Paid-in capital
0.75
2.35
Retained earnings
-49.2
-123
Other comprehensive income
0
0.06
Shareholders' equity
-48.5
-121
Total equity
-48.5
-121
Total liabilities and equity
55.5
153
Shares outstanding
0.74
0.75
Cash flow statement
FY2025
FY2025
Net income
-26.5
-70
Stock-based compensation
0.25
1.44
Change in payables
0.65
-0.12
Cash from operations
-23.7
-71.6
Capital expenditures
0
-0.02
Purchases of investments
0
-144
Cash from investing
0
-119
Stock issued
0
0.16
Cash from financing
60.5
159
Net change in cash
36.8
-31.3
Free cash flow
-23.7
-71.6
Interest paid
0.1
0
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $116.57 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-67.3%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
174.8%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
1.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
16.7x
Current assets / current liabilities.
Quick ratio
15.5x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
15.5x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$111.91
Net income per basic share, as reported (split-adjusted).
FCF per share
-$96.14
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$96.11
Cash from operations / diluted weighted shares.
Book value per share
-$161.40
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
FCF yield
-1.5%
Free cash flow / market cap.
Earnings yield
-1.4%
Net income / market cap (the inverse of P/E).
Was Veradermics, Inc profitable in fiscal 2025?
No. It reported a net loss of $70.0M.
How much free cash flow did Veradermics, Inc generate in fiscal 2025?
Cash from operations of $71.6M minus capital expenditures of $24.0K left free cash flow of -$71.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.